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Inﬂammation is a variable feature of osteoarthritis (OA), associated with joint symptoms and progression
of disease. Signs of inﬂammation can be observed in joint ﬂuids and tissues from patients with joint
injuries at risk for development of post-traumatic osteoarthritis (PTOA). Furthermore, inﬂammatory
mechanisms are hypothesized to contribute to the risk of OA development and progression after injury.
Animal models of PTOA have been instrumental in understanding factors and mechanisms involved in
chronic progressive cartilage degradation observed after a predisposing injury. Speciﬁc aspects of
inﬂammation observed in humans, including cytokine and chemokine production, synovial reaction,
cellular inﬁltration and inﬂammatory pathway activation, are also observed in models of PTOA. Many of
these models are now being utilized to understand the impact of post-injury inﬂammatory response on
PTOA development and progression, including risk of progressive cartilage degeneration and develop-
ment of chronic symptoms post-injury. As evidenced from these models, a vigorous inﬂammatory
response occurs very early after joint injury but is then sustained at a lower level at the later phases. This
early inﬂammatory response contributes to the development of PTOA features including cartilage erosion
and is potentially modiﬁable, but speciﬁc mediators may also play a role in tissue repair. Although the
optimal approach and timing of anti-inﬂammatory interventions after joint injury are yet to be deter-
mined, this body of work should provide hope for the future of disease modiﬁcation tin PTOA.
Published by Elsevier Ltd on behalf of Osteoarthritis Research Society International.Introduction
Joint injury is a well-established risk factor for development of
OA1; approximately 12% of all OA cases may be due to prior joint
trauma2. After a joint injury, surgery to re-stabilize the joint is often
indicated for functional recovery and pain relief. Altered biome-
chanics from injury put the patient at risk for progressive joint
degeneration3, but surgical re-stabilization does not reduce this
risk4. Many investigators have speculated that molecular and
cellular alterations to joint tissues resulting from injury are not
readily reversible by joint stabilization. It is therefore important to
understand the biological mechanisms triggered by joint injury,
and how they change over time, to develop more successful inter-
vention strategies for prevention and treatment of post-traumatic
OA (PTOA).C.R. Scanzello, University of
f Rheumatology, 3400 Spruce
. Tel: 1-(215)-823-5800x5666
Lieberthal), nishasam@mail.
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eoarthritis Research Society InternLow-grade cellular inﬁltration, cytokine production, and in-
ﬂammatory activation of articular chondrocytes, synoviocytes and
other joint tissue cells are common in OA. Human studies and an-
imal models have revealed details about the course and nature of
inﬂammatory mediator production, inﬂammatory pathway acti-
vation and synovial cellular inﬁltration after joint injury. The
importance of inﬂammatory cytokines in promoting enzymatic
mediators of cartilage catabolism (i.e., MMPs, ADAMTS enzymes)
makes early inﬂammation a suitable target for prevention of PTOA.
In this review, we will focus on recent literature regarding time-
dependent production of speciﬁc inﬂammatory mediators in both
clinical studies as well as animal models of PTOA and the multiple
sources of inﬂammation in OA both local and systemic. Further, we
discuss current understanding of the activation of inﬂammatory
pathways as well as pharmacologic targeting of speciﬁc mediators
of inﬂammation using disease models of PTOA.Methods
A PUBMED search limited to the past 10 years was pursued for
this narrative review using the following strategies: (1)ational.
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munity AND osteoarthritis NOT Rheumatoid”, and (3) “Inﬂamma-
tion AND osteoarthritis NOT Rheumatoid” which together yielded
1358 references. We removed review articles, redundant citations
and irrelevant references. We limited references that were more
than ﬁve years old to those that provide important contributions
and context. A small number of references not revealed in the
search but known to the authors were added.
Inﬂammatory mediator production after joint injury
Common injuries associated with PTOA development include
disruption of the anterior cruciate ligament5, meniscus6,7 and intra-
articular fracture8. These injuries result in hemarthrosis, chon-
drocyte death and bruising of underlying bone, and in the release of
inﬂammatory mediators in the acute post-injury period. A recent
study reported synovial ﬂuid (SF) levels of inﬂammatory cytokines
from 111 patients presenting with traumatic ACL tears, and cate-
gorized levels according to time since injury9. Fluidwas aspirated at
presentation, which ranged from the day of injury to 23 days later.
Levels of IL-1b, IL-6, IL-8 and TNFa were highest in ﬂuids aspirated
on day 0e1 post-injury, but then remained elevated compared to
uninjured controls. Levels of cytokines peaked one day earlier than
markers of cartilage proteoglycan breakdown, and IL-8 and TNFa
were higher in those with concomitant osteochondral fracture10.
Similar trends were seen in a study of patients aspirated within
48 h of ACL injury11.
Anti-inﬂammatory molecules are also observed post-injury.
Following ACL injury, SF levels of IL-10 were elevated in the ﬁrst
two weeks post-injury, but were lower in ﬂuids aspirated later11,12.
In vitro, exposure to IL-10 along with IL-4 protects cartilage from
inﬂammatory effects of blood products, suggesting a potential
chondroprotective role in response to the hemarthrosis that often
accompanies ACL injury13. A study of human subjects using
microdialysis catheters showed an increase in IL-10 in the joint
capsule following exercise14, suggesting IL-10 may also contribute
to the beneﬁcial effects of exercise. IL-1 receptor antagonist (IL-
1Ra), the natural antagonist of IL-1a and b, is detectable in SF from
uninjured joints15. Levels of IL-1Ra are reported to be elevated in SF
aspirated in the acute phase after ACL injury, but then lower than
normal in ﬂuids aspirated later (three to > six weeks after injury)16.
A decrease in IL-1Ra levels could leave the activity of IL-1 unop-
posed in the injured joint. However, there is some disagreement as
to whether SF IL-1a or b are consistently elevated following
injury16,17. SF handling and method of detection are variables that
might explain differences between studies, but whether SF levels of
a speciﬁc molecule necessarily reﬂect local tissue concentration
and importance in pathogenesis is unclear.
After the acute phase, cytokine concentrations generally
decrease but some are reported elevatedmonths to years after joint
injury. In a study of chronic ACL tears (aspirated over 6 months
since injury) there was a modest difference in the concentration of
SF IL-1b between patients and healthy controls, and levels corre-
lated with the degree of chondral damage18. SF IL-1Ra levels were
also higher compared to controls. Other authors have reported that
SF IL-1 levels drop to normal in patients aspirated up to three
months after injury, while levels of IL-6 and TNFa remained
elevated 6 months post-injury19. None of these studies employ
longitudinal sampling of SF from the same patients. A recent review
of cross-sectional studies from ACL-injured patients20 concluded
that in the ﬁrst week post-injury20, levels of IL-6, IL-8, and IL-1Ra
were consistently elevated, while there was more variability in
reported levels of IL-1a and b. In the subacute period (1 weeke2
months), IL-6 levels remain elevated across studies, and other cy-
tokines and chemokines such as MCP-1, MIP-1b, and IFNg havebeen reported. In the subacute to chronic phase (2 months to >1yr),
while IL-6 and IL-8 remain elevated, IL-1Ra levels were often re-
ported lower than controls. TNFa elevations in the subacute period
persist into the chronic phase (>1yr post-injury). There are clearly
different phases of inﬂammation following injury21. The initial
injury results in acute tissue damage, prompting a robust release of
pro- and anti-inﬂammatory mediators. We speculate that the pro-
inﬂammatory response in certain patients lacks adequate control
post-injury, thereby perpetuating chronic inﬂammation and tissue
damage leading to PTOA (Fig. 1).
Soluble inﬂammatory mediators in animal models
A variety of animal models that involve injury by surgical,
traumatic or chemical means22 are used to understand biologic and
mechanical mechanisms in PTOA. Commonly used surgical models
include meniscectomy or ACL transection in rodents, rabbits, and
sheep. Loading injury models in rodents, including noninvasive
tibial plateau fracture, have also been developed23,24. By altering
the mechanism or extent of injury, the cadence of OA progression
can be altered25.With appreciation of the post-injury inﬂammatory
response seen in patients, these models are being used to investi-
gate the role of inﬂammation in PTOA.
Data from multiple species demonstrate production of inﬂam-
matory mediators post-injury, including cytokines and chemokines
observed in human patients26e30. Recent studies address how in-
ﬂammatory gene expression varies with time after injury in com-
mon rodent models. Wei and colleagues31 compared cartilage
transcriptomic proﬁles in rats undergoing meniscal transection to
sham-operated controls at days 3, 7 and 21 post-injury. 337
differentially expressed genes were observed at day 3, with smaller
numbers at day 7 (79) and day 21 (112). CCL2 (MCP-1), a chemokine
involved in macrophage recruitment, was upregulated at all three
time-points although highest at day 3. Pathway analysis revealed
that genes involved in extracellular matrix (ECM) turnover and the
inﬂammatory response were observed. mRNA expression analysis
in the murine destabilization of medial meniscus (DMM) model
also provided insight on time-dependent transcriptional regulation
after injury32e34. In this slowly progressive model, global upregu-
lation of transcription was seen early (2e4 weeks), followed by
down-regulation at 8 weeks and more modest up-regulation again
at 16 weeks post-DMM indicating distinct phases of transcriptional
activity after injury. Consistent with other investigators, genes and
pathways related to ECM remodeling were activated most strongly
indicating an attempted reparative response. But genes involved in
inﬂammatory processes were also identiﬁed, notably the chemo-
kine CCL21 which was upregulated at all post-DMM time points
examined (2, 4, 8 and 16 weeks post-surgery). The signiﬁcance to
disease of this particular chemokine, known for controlling normal
trafﬁcking of lymphocytes and dendritic cells, has yet to be deter-
mined. Taken together, these studies demonstrate that activation of
inﬂammatory genes occurs most robustly early after injury, but is
sustained at lower levels, in agreement with human observational
data.
As surgical intervention does not reduce the risk for PTOA, an
important question is whether acute post-injury inﬂammation is
independent of joint instability. Two recent approaches have
addressed this question. In an ovine model of ACL tear followed by
immediate reconstruction to re-establish stability35, cartilage
changes were observed 2 weeks after, and persisted but did not
progress signiﬁcantly by 20 weeks post-surgery36. Similarly, IL-1b,
IL-6 and IL-8 were increased in synovium at 2 weeks, but
normalized by 20 weeks suggesting resolution of acute inﬂamma-
tion in the absence of chronic instability. The authors concluded
that the immediate post-injury inﬂammatory response contributes
Fig. 1. Perpetuation of inﬂammation as a mechanism leading to PTOA: Joint injury sets off a robust acute inﬂammatory response that includes production of both pro- and anti-
inﬂammatory cytokines, molecular “danger” signals such as the S100A family of proteins, and activation of the complement cascade. In certain individuals the inﬂuence of anti-
inﬂammatory factors (i.e., IL-10 and IL-1RA) produced in the early post-injury period may allow for resolution of inﬂammation and reduce the risk of progressing to PTOA. However,
perpetuation of inﬂammation via continued activation of innate inﬂammatory pathways may promote progression to PTOA in the injured joint. A number of factors may lead to
perpetuation of inﬂammation after joint injury. These include the severity of the initial injury, the balance of pro- and anti-inﬂammatory factors produced in the acute and subacute
post-injury periods, and repeated macro- or micro-injury which can promote continuous cycles of inﬂammatory activation involving innate pathways such as the complement
cascade and danger-signal mediated pathways. Anti-inﬂammatory approaches (i.e., intraarticular IL-1Ra) to interfere with the acute phase (dashed red line) are already being tested
in animal models and hold promise for prevention of PTOA. Whether resolution of chronic inﬂammation (dashed red arrow) can be accomplished to slow progression of structural
change and chronic disability remains to be determined.
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model, an injury was created in New-Zealand white rabbits by
drilling two holes into the subchondral bone in a non-load bearing
area of the inter-condylar notch37. Synovial expression levels of IL-
1b, IL-6, and IL-8 as well as IL-1Ra were increased 2e3 fold within
72 h of injury, but then decreased to baseline by 3 weeks. Dexa-
methasone injected intra-articularly reduced expression of in-
ﬂammatory markers and decreased cartilage degeneration in this
model38. These two recent studies suggest that an early biologic
inﬂammatory response to joint tissue injury can occur in the
absence of gross instability, and that the early inﬂammatory
response contributes to PTOA development. How much of this
response is related to surgically induced bleeding into the joint
remains unclear, but may be relevant to patients with joint injuries
associated with hemarthrosis.Post-injury inﬂammation reﬂects activity of multiple joint tissues
It is likely that multiple joint tissues contribute to inﬂammation
after joint injury. Synovial macrophages, ﬁbroblasts and chon-
drocytes are sources of cytokines and chemokines39, and a wide
variety of other inﬂammatorymolecules. Infrapatellar fat pads from
patients with knee OA have increased numbers of macrophages,
granulocytes and lymphocytes40, and this tissue can contribute to
production of inﬂammatory cytokines in knee OA patients41,42.
Fibrocartilaginous structures such as the meniscus in the knee43
and the labrum in the hip44 respond to and produce inﬂamma-
tory mediators. Understanding which tissues and cell typescontribute to inﬂammation has important implications for thera-
peutic targeting. Several studies have focused on the cell/tissue
source of soluble pro-inﬂammatory products and enzymatic me-
diators of progressive cartilage loss (proteases of the MMP and
ADAMTS families). Haslauer and colleagues45 recently studied
mRNA expression of proteases in joint tissues from mini-pigs after
ACL transection. Synovium, ligament and scaffold tissue were
predominant sources of MMP-13 and ADAMTS-4 in the ﬁrst two
weeks after ACL tear. MMP-13 increased up to 350-fold in synovium
and 1000-fold in ligament by 14 days post-injury. In cartilage,
ADAMTS-4 levels did not change while MMP-13 was down-
regulated. These results are consistent with ACL-transection
models in rabbits and rats46e48, rodent meniscectomy30,49
models, and observations in canine cranial cruciate ligament
tears27. Thus, non-cartilaginous soft tissues may be important
sources of inﬂammatorymolecules and proteases that contribute to
cartilage matrix catabolism early after injury. Whether anti-
inﬂammatory targeting of speciﬁc extra-cartilaginous cells or tis-
sues will improve interventions is yet to be determined.Synovial thickening and cellular inﬁltration
Cellular inﬁltration into synovium also occurs in patients with
joint injuries. Macrophage content of the synovium is increased in
patients with knee OA and patients with joint injuries39,50,51. Mo-
lecular markers of macrophage activation in SF and serum were
recently associated with progression of joint space narrowing and
severity of pain in knee OA52. In patients presenting with meniscal
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correlated with knee pain53, but reports in other injury populations
are lacking. Cellular inﬁltration in the early phases of joint injury in
humans, prior to OA onset, needs to be more fully investigated.Synovial inﬂammation in animal models
Recent data has suggested that synovial cellular inﬁltration and
lining layer thickening are frequent ﬁndings in both large and small
animal models of PTOA23,36,37,54,55. A synovial response was
recently demonstrated post-injury in the DMM model using a
comprehensive histological evaluation54. Synovitis was most se-
vere in the ﬁrst two weeks after surgery in both DMM and sham-
operated limbs, but dropped to control levels by 8 weeks post-
surgery in sham, and sustained out to 12e16 weeks in DMM-
operated limbs. At least two noninvasive PTOA models have
shown that the severity of the synovial reaction may be related to
the severity of injury. Lewis and colleagues used a low or high-
energy load applied to the murine knee joint to create a tibial
plateau fracture noninvasively23. The degree of thickening and
cellular density correlated to the severity of fracture. Similar results
were seen in a murine model of repetitive load, where synovial
thickening was reported 5 days post-injury and related to energy of
the load applied56. Inﬁltrating cell types were not examined in
these models, but clearly both invasive and noninvasive models of
PTOA may be useful to examine the role of synovial pathology and
cellular inﬁltration post-injury. The available data suggests that
synovial changes occur early post-injury, are sustained at lower
levels, and are related to severity/extent of injury (Table I).
In the DMMmodel, Jackson and colleagues used ﬂow cytometric
analysis of cells from synovial tissue 1-week post-DMM to show
that total cell numbers and proportions of inﬂammatorymonocytes
and macrophages were increased54. Furthermore, mice deﬁcient in
protease-activated receptor-2 (PAR-2) were partially protected
from OA. PAR-2 deﬁciency caused less robust macrophage re-
sponses to LPS stimulation, but did not alter chondrocyte activity,
suggesting that protection was mediated by the reduction in
macrophage activation. Synovial macrophage depletionwas shown
to protect against osteophytosis and MMP-mediated cartilage ma-
trix degradation in the collagenase model of joint instability57,58,
but has not been reported in injury models. Synovitis and cartilage
erosion following ACL transection were reduced in CD4 deﬁcient
mice59, and reduced production of the chemokine MIP-1g was
hypothesized to be a potential mechanism. In the same model,
cartilage erosion progressed more slowly in CD8 deﬁcient mice60.
These studies support a role for both inﬁltrating macrophages and
T-lymphocytes post-injury in disease progression. The effects of
these cell types at different stages and the mechanisms by which
they impact disease need further exploration. Other leukocyte
populations such as dendritic cells have been noted in certain
models61, but signiﬁcance to disease has not been established.Table I
Important features of the inﬂammatory response after joint injury supporte
Feature
Signs of inﬂammation occur early after joint injury.
Inﬂammation is sustained at lower levels.
Patterns of inﬂammation change with time after injury.
The extent/severity of the initial injury inﬂuences severity of synovial inﬂ
Multiple joint tissues and cell types contribute to inﬂammation after inju
Inﬂammation can occur even in the absence of joint instability.
Inﬂammation contributes to cartilage damage and pain responses after jo
Certain aspects of post-injury inﬂammation may be protective and impor
Inﬂammation is a modiﬁable feature of PTOA.Systemic inﬂuences on inﬂammation
Just as local inﬂammatory networks have been shown to play a
role in osteoarthritis (OA) pathogenesis, systemic factors have also
been implicated, and the strongest inﬂuence appears to be obesity.
Obesity has long been recognized as a risk factor for OA62. While
some of the risk may be due to increased joint loading, the asso-
ciation of obesity with the development of OA in non-weight
bearing joints suggests that other mechanisms are involved63.
The systemic effect of obesity on OA development is believed to be
mediated, in part, by inﬂammatory substances (free fatty acids,
reactive oxygen species cytokines and adipokines) produced by
adipose tissue which can be released into the bloodstream64. Spe-
ciﬁc adipokines such as the molecules leptin and adiponectin have
inﬂammatory and catabolic inﬂuences on joint tissues65. In addi-
tion, obesity is associated with higher levels of IL-6 and TNFalpha66.
In addition, a number of studies have suggested that weight loss is
an important intervention in the management of OA. The results of
the IDEA trial indicated that moderate weight loss affects both
biomechanical and inﬂammatory pathways in OA patients, as
measured by knee compressive forces and IL-6 levels respectively67.
A moderate reduction in total fat mass is associated with lower CRP
levels and a moderate loss of abdominal fat mass is associated with
reduced levels of IL-668. How systemic inﬂammation from obesity
may modulate the post-injury inﬂammatory response in patients
suffering pre-disposing joint trauma has yet to be studied, but it is
likely that multiple risk factors contribute to overall risk of OA
development and progression in an individual patient. Data from
animal models has indicated a complex interplay between obesity,
systemic inﬂammation, and physical activity and joint loading.
When fed a high-fat diet, mice are more prone to develop knee OA,
and exhibit changes in systemic inﬂammatory and anti-
inﬂammatory mediators (including adiponectin and leptin)69.
Moderate wheel-running had a protective effect against the
development of OA70. But surprisingly the effects of exercise were
not mediated by weight loss, but rather through an effect on sys-
temic inﬂammatory networks. These series of investigations in
mice not only support a systemic inﬂammatory inﬂuence of obesity
on OA, but also point to a systemic anti-inﬂammatory effect of
exercise.Anti-cytokine and chemokine interventions
The impact of cytokines in PTOA has recently been reviewed71. A
few notable cases will be discussed, starting with IL-1. Despite
differing reports on IL-1 concentration after joint injury, this
cytokine is a potent mediator of cartilage catabolism, and many
models have supported its importance in PTOA. Early work
demonstrated that intraarticular injection of IL-1Ra after canine
ACL transection reduced osteophytosis and cartilage lesions72.
Adenoviral transfer of IL-1Ra into equine joints has shown73,74.d by recent work in patients and animal models of PTOA
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in the DMMmodel75, and IL-1 antagonism reduced PTOA after tibial
plateau fracture in mice76,77. Zhang et al.78 combined anti-
inﬂammatory approaches, using retroviral transduction to over-
express human IL-10 and IL-1Ra in rabbits after excision of the
medial collateral ligament and medial meniscectomy. Both IL-10
and IL-1Ra expression attenuated cartilage damage 2 weeks post-
injury, and over-expression of both proteins was superior to
either alone. Small studies have been carried out in patients.
Intraarticular injection of IL-1Ra in 160 patients with knee OA did
not improve mean symptom scores compared to placebo79. In
contrast, a study of 11 patients given intra-articular IL-1Ra within
30 days of ACL injury demonstrated improvement in symptoms
compared to placebo at 2 weeks80. Although data is limited, it is
possible that this strategy may be more efﬁcacious in the early
post-injury phase.
The receptor for IL-17 is expressed in OA synovium and carti-
lage81. IL-17 and can promote release of other inﬂammatory cyto-
kines from chondrocytes and synovial ﬁbroblasts in vitro81,82.
Therefore, Chen et al. developed a DNA aptamer that effectively
blocked the IL-17 receptor83. In the murine DMM model, intra-
articular injection reduced synovial thickening and expression of
IL-6. Protection from cartilage degeneration post-injury was not
observed, however the importance of synovial inﬂammation in
symptom development may support therapeutic targeting of sy-
novial responses post-injury.
A number of chemokines have been explored as potential tar-
gets. MCP-1 is associated with knee pain in patients with knee
injuries84,85, and mice deﬁcient in the high afﬁnity MCP-1 receptor
(CCR2) are protected from developing pain-related behaviors post-
DMM86. CCR2 deﬁciency had no effect on cartilage degeneration. In
contrast, deﬁciency of CCR5 was shown to partially protect against
cartilage erosion in this same model87. Interestingly, loss of CCR5
did not impact synovitis or bone remodeling, suggesting a direct
effect on cartilage. CXCR2 may protect cartilage by promoting
phenotypic homeostasis88. Genetic loss of CXCR2 in mice resulted
in more severe OA after DMM surgery. Chemokines clearly inﬂu-
ence PTOA development in both positive and negative ways, and
can inﬂuence development of structural disease and symptoms.
Whether targeting speciﬁc chemokines or their receptors will be
effective clinically remains to be tested; systemic effects need to be
carefully considered.
PTOA progression risk is likely related to an inﬂammatory pro-
ﬁle rather than the effect of a single mediator. The available data
suggests that there is a crucial balance between protective and
deleterious effects of the initial inﬂammatory response to injury
that needs to be better understood. This balance likely reﬂects the
role of inﬂammation in tissue repair responses. As individual in-
ﬂammatory mediators can have cell-speciﬁc and time-dependent
effects, expression in various joint tissues and times post-injury
needs further investigation. Alternatively, targeting speciﬁc path-
ways leading to chronic inﬂammation, rather than speciﬁc media-
tors, may provide promise. Recent studies have uncovered a few
molecular pathways that are important in triggering and perpetu-
ating inﬂammation after joint injury.
Inﬂammatory pathway activation in animal models
The complement cascade
The complement proteolytic cascade is an essential innate in-
ﬂammatory mechanism for clearance of pathogens and damaged
cells [reviewed in89]. Complement deposition in synovium from
patients with meniscal tears was reported in the past90. More
recently, it was reported that chondrocytes and synovial macro-
phages actively produce complement components and inhibitors,and that production is increased in OA91,92. There are several mo-
lecular components of cartilage matrix that can activate or inhibit
the complement cascade93e95. Mice with impaired ability to
generate the complement membrane attack complex are partially
protected from development of OA after surgically induced
meniscal injury, and therapeutic targeting of complement was also
effective96. The optimal timing, risks and beneﬁts of such a strategy
for use in patients needs further evaluation.
Molecular “danger signal” and pattern-recognition receptor
pathways
Pattern-recognition receptor systems including the Toll-like
receptors (TLRs) NOD-like receptors (NLRs) and the receptor for
advanced glycation end-products (RAGE), are utilized by the innate
immune response to tissue injury97. In the setting of non-infectious
tissue damage, these receptors respond to a variety of damage-
associated molecular patterns (DAMPS), also termed “danger sig-
nals” or “alarmins”, released during cellular stress and ECM dam-
age. Activation of these receptors promotes inﬂammatory signaling,
cytokine and chemokine production. “Danger signals” such as
HMGB198, S100A8 and S100A999, and tenascin-C100 can be pro-
duced by cells subjected to oxidative and metabolic stress, or
elaborated from damaged ECM101. The role of selected DAMPs and
the receptors that bind them have been studied in PTOA.
S100A proteins are produced by multiple cell types (macro-
phages, neutrophils, etc) and found in serum and synovium of OA
patients102,103. Human chondrocytes produce these molecules, and
exposure of cartilage explants to S100A8 and S100A9 promoted
catabolic (MMP-1, MMP-3, MMP-13, IL-6, IL-1b) and suppressed
anabolic gene expression (aggrecan and Collagen type II) in a TLR-4
dependent manner104. Moreover, S100A9 deﬁcient mice exhibited
reduced disease in the collagenase model, but not the DMMmodel
of OA104,105, and disease was inhibited by pharmacologically
reducing S100A9 expression106. The differential effects in these two
models were attributed to more robust synovial activation in the
collagenase model, which is induced by intra-articular injection of
bacterial collagenase leading to instability of connective tissues.
Whether results are applicable to injury-induced PTOAmodels that
exhibit more extensive synovial reaction than DMM remains to be
tested.
Elevated levels of Tenascin-C (TnC), a danger signal which binds
to TLR4, are observed in the joint after injury107,108. TnC induces
GAG release and aggrecanase activity in cartilage explants109 and
chondrocyte cultures110, and expression correlates with aggreca-
nase activity in a rat ACL-tear model110. But in vivo studies in
deﬁcient mice (TnC/) have revealed a predominant role for TnC
in supporting cartilage repair. TnC/ mice develop cartilage
erosion more rapidly after ACL and MCL transection, and cartilage
repair is delayed in a focal cartilage defect model111. It is possible
that the effect of TnC is modiﬁed by other factors present in vivo,
but additional work is necessary to clarify.
An interesting recent study showed that a 32-mer peptide of
aggrecan, generated by sequential enzymatic cleavage in joints of
patients with OA, can promote catabolism and suppress anabolic
gene expression in murine and human chondrocytes, synovial ﬁ-
broblasts and macrophages101. MyD88 and TLR-2 were shown to
mediate these effects. Whether this peptide plays an important role
in modulating disease progression after joint injury in vivo remains
to be tested. Enzymatic aggrecan degradation plays an important
and early role in development of progressive cartilage damage in
multiple PTOA models, thus highlighting its potential for future
therapeutic manipulation.
The pro-inﬂammatory effects of molecular danger signals are
mediated through a variety of pattern recognition receptors. Of
these receptors, the TLRs have beenmost studied in PTOA. Catabolic
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response to many of the danger signals mentioned previously are
mediated through TLR-2 or TLR-4. However, mice deﬁcient in
expression of TLR-1, -2, -4, or -6, as well as the key TLR signaling
adaptor molecule MyD88 were not protected from development of
cartilage erosion 8 weeks after partial meniscectomy112. Other
timepoints, and pain-related outcomes particularly relevant to
inﬂammation have not been examined. The data regarding S100
proteins105 points to the importance of investigating multiple
models, as the mechanism of disease induction may be an impor-
tant variable impacting results. Therefore, whether observations
from this study extend to other models and human PTOA has yet to
be determined.Conclusion
Activation of inﬂammatory mechanisms is critical to develop-
ment of PTOA, and part of the joint response to injury. Aspects of
inﬂammation observed after injury in humans include inﬂamma-
tory mediator production (i.e., cytokine and chemokines, DAMPs),
cellular inﬁltration and innate inﬂammatory pathway activation
involving multiple tissues. These aspects are often recapitulated in
animal models of PTOA in a time-dependent manner. Multiple
models have demonstrated that inﬂammation after injury occurs
early, but is sustained and modiﬁable (Table I). However, we still
have a limited understanding of the speciﬁc changes that corre-
spond to inﬂammatory responses over time after different injuries.
Inﬂammatory response to joint injury may be altered by aging and
systemic factors, providing a molecular context for the interaction
of multiple OA risk factors (i.e., joint injury, age, obesity). Weight
loss and physical activity can be accompanied by anti-inﬂammatory
effects in both patients and animal models, providing hope that the
systemic effects of obesity on OA could be mitigated by non-
pharmacologic approaches. Models have also revealed speciﬁc
targets that show potential to slow cartilage erosion, synovitis, and/
or pain-related outcomes. However, results to date have illustrated
the complexity of the inﬂammatory response post-injury, which
exerts both deleterious and potentially protective roles. This
complexity may relate to multiple cellular sources and targets in
the joint, and the role of inﬂammation in tissue repair. Therefore,
multiple models exhibiting different phenotypes need to be
examined in order for a comprehensive picture of the impact of
inﬂammation in PTOA to emerge. The strong association of
inﬂammation with pain and joint dysfunction in patients necessi-
tates examination of symptomatic measures in PTOA models when
possible. It is likely that the nature and impact of future anti-
inﬂammatory intervention will be dependent on time post-injury,
and tissue or cell type targeted. And although early intervention
is likely important for prevention of cartilage deterioration, there
may be more than one optimal “window of opportunity” for tar-
geted anti-inﬂammatory approaches to impact progression or
development of chronic disability and pain (Fig. 1).Author contributions
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